PERT for pancreatic enzyme insufficiency in pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests if a pancreatic enzyme replacement therapy (PERT) helps weight loss caused by tumors in the head of the pancreas. It may improve nutrition for people with advanced pancreatic cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that cannot be removed by surgery, or has spread to nearby areas or other parts of the body.
- Your tumor is in the head of the pancreas.
- Your main pancreatic duct is widened, seen on a CT scan, MRI, or endoscopic ultrasound.
- You have lost at least 5% of your usual body weight recently.
- You have not had this type of enzyme therapy before.
- You have not had surgery on your upper digestive tract or pancreas.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called PERT (pancreatic enzyme replacement therapy) helps people with severe acute pancreatitis who have lost pancreatic tissue (necrosis) and significant body weight. The goal is to see if replacing missing digestive enzymes improves nutrition and recovery.
This trial tests whether a pancreatic enzyme replacement therapy (PERT) can help people who still have digestive problems after a recent episode of acute pancreatitis. The goal is to see if it improves symptoms like stomach pain, bloating, or diarrhea.
This study tests a new digestive enzyme supplement (NHS7108) in adults whose pancreas doesn't make enough enzymes to digest food properly. The trial evaluates whether this new treatment is safe and helps improve fat digestion better than current treatments.
This trial tests a new blood test to measure how well your pancreas works. It may help people with chronic pancreatitis understand their condition and quality of life.
This study tests a protein drink with digestive enzymes for people with chronic pancreatitis who are underweight. It aims to help improve nutrition and weight.
This trial tests EF-009, a study medicine, in adults with pancreatic cancer that doctors consider “borderline resectable” or “unresectable.” The goal is to see how safe it is and how well it works for this situation.
Hear when a new Unresectable Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.